Ir.retrophin.com

Ir Retrophin. Inc. 's business for stockholders, potential investors, and financial analysts.

Today's Ir.retrophin.com headlines: Observe fresh posts and updates on Ir Retrophin. This site’s feed is stale or rarely updated (or it might be broken for a reason), but you may check related news or Ir.retrophin.com popular pages instead. It is generally safe for browsing, so you may click any item to proceed to the site.

News, stories and media buzz related to Ir Retrophin

Subscribe to related news

Gw Pharmaceuticals Plc Reports Fourth Quarter And Year-End 2015 Financial Results And Operational Progress
via whotrades.olanola

The following excerpt is from the company's SEC filing. - Three Phase 3 Epidiolex clinical trials fully recruited above target sample size – on track for initial data in Q1 2016 - - Significant clinical activity in multiple cannabinoid pipeline programs...
Meeting With Amarantus Confirms Fundamental Turnaround
via bionapcfa.blogspot

By Jason Napodano, CFA We recently sat down with Amarantus Bioscience Holdings (AMBS) CEO, Gerald Commissiong. The meeting confirmed our belief that Amarantus is in the midst of a fundamental turnaround and has significant growth potential over the...
The 2016 BPI Awards: Honoring the People, Organizations, and Technologies in Global Biotherapeutics
via bioprocessintl

BPI publisher, Brian Caine Since 2003, the mission of BioProcess International has been to connect biopharmaceutical scientists and decision makers to the science, technology, and expertise that can positively influence and improve existing bioprocesses...
Dermira and UCB Announce Start of Phase 3 Program for CIMZIA(R) (certolizumab pegol) in Psoriasis
via baycitycapital

Menlo Park, CA, and Brussels, Belgium — Dermira, Inc., a specialty biopharmaceutical company focused on bringing innovative and differentiated medical dermatology products to dermatologists and their patients (Nasdaq:DERM), and UCB, a global biopharmaceutical...
Chi-Med 2016 Interim Results
via saudiindustrydaily

HONG KONG, CHINA—(Marketwired – Aug 2, 2016) – Hutchison China Meditech Limited ( NASDAQ : HCM ) Nasdaq: HCM Hutchison China MediTech Limited (“Chi–Med”) Reports Interim Results for the Six Months Ended June 30, 2016, Provides 2016 Financial Guidance...

Ir.retrophin.com popular pages

Investor Relations - Retrophin, Inc.

The Investor Relations website contains information about Retrophin, Inc. business for stockholders, potential investors, and financial analysts.
Press Releases - Retrophin, Inc.

Press Releases SAN DIEGO, March 07, 2017 (GLOBE NEWSWIRE) -- Retrophin, Inc. (Nasdaq:RTRX) today announced that Stephen Aselage, chief executive officer, will present at the Barclays Global Healthca...